Why surgery was performed for IPMN and the outcomes
Official title: Optimizing Preoperative Surgical Decision-making for Intraductal Papillary Mucinous Neoplasms: The Role of Intent of Surgery
Run by NYU Langone Health · NCT07216521 · Data updated 2026-11-12
This project looks at medical records of adults who had surgery for IPMN to see if operations were done for suspected cancer versus incidental findings and how those patients did afterward.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 14 sites (Phoenix, Arizona and 13 other locations) |
| Status | Recruiting |
| Started | September 15, 2025 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | October 14, 2025 |
| Trial ID | NCT07216521 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who underwent surgical resection for IPMN (including low- or high-grade dysplasia or invasive carcinoma) between July 1, 2015 and July 1, 2025 and who did not have concurrent pancreatic ductal adenocarcinoma are the population studied.
✕Probably not a fit
Patients managed nonoperatively or patients with concurrent pancreatic ductal adenocarcinoma are not included and therefore are unlikely to directly benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter retrospective cohort study of adults who underwent surgical resection for intraductal papillary mucinous neoplasms (IPMN) between July 1, 2015 and July 1, 2025. Investigators will classify the documented intent for surgery and quantify how often IPMN-associated cancers were diagnosed as overt pancreatic cancer with incidental IPMN on pathology. The study will compare clinicopathologic features and clinical outcomes between cancers detected during surveillance versus those found incidentally. Finally, the team will refine risk features among patients taken to surgery to identify optimal predictors of malignant IPMN (high-grade dysplasia or invasive cancer).
Why it matters
Potential benefit: If successful, the findings could help doctors better select which IPMNs need surgery and which can be safely watched, potentially reducing unnecessary operations and improving detection of cancers that need treatment.
How similar studies have gone: Prior retrospective studies have described IPMN outcomes and risk factors, but this multicenter effort focusing specifically on surgical intent and direct comparison of surveillance-detected versus incidental IPMN-derived cancers is a more targeted and novel analysis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients (18 years old of greater) who underwent surgical resection for IPMN (including low-, high-grade dysplasia, or invasive carcinoma) between July 1, 2015 and July 1, 2025. Exclusion Criteria: * Patients with concomitant pancreatic ductal adenocarcinoma (PDAC)
Where it's running
-
Mayo Clinic
Phoenix, Arizona, United States Recruiting -
Johns Hopkins University
Baltimore, Maryland, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Mayo Clinic
Rochester, Minnesota, United States Recruiting -
NYU Langone Health
New York, New York, United States Recruiting -
Memorial Sloan Kettering
New York, New York, United States Recruiting
Show 8 more locations
-
Duke University
Durham, North Carolina, United States Recruiting -
MD Anderson Cancer Center
Houston, Texas, United States Recruiting -
Nanjing University
Nanjing, China Recruiting -
Heidelberg University
Heidelberg, Germany Recruiting -
San Raffaele Hospital
Milan, Italy Recruiting -
Padua University
Padua, Italy Recruiting -
University of Amsterdam
Amsterdam, Netherlands Recruiting -
University of Utrecht
Utrecht, Netherlands Recruiting
Study contacts
- Principal investigator: Greg Sacks, MD MPH PhD — NYU Langone Health
- Study coordinator: Camila Hidalgo Salinas, MD
- Email: Camila.hidalgosalinas@nyulangone.org
- Phone: 347-266-1376
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
AI-enhanced low-dose CT to screen for pancreatic cancer
This project will test whether an AI tool called PANDA can read low-dose CT scans to find early pancreatic cancer in people aged 50 and older.
-
AI-based early detection of pancreatic cancer using routine CT scans
This study is testing an AI system that uses regular CT scans to see if it can help find pancreatic cancer early in people who are at high risk.
-
Exploring biomarkers for early detection of pancreatic tumors
This study is trying to find early warning signs in blood, urine, and other samples from patients with a specific type of pancreatic tumor to see if they can help predict when it might turn cancerous.
-
Registry for pancreatic cysts at UCSF
This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.